Previous 10 | Next 10 |
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held in New York City on March 21, 2019. Unique to the medical and bi...
Alliance for Regenerative Medicines’ Seventh Annual Investors Conference Genprex, Inc. (NASDAQ: GNPX ), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presentin...
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring clinical-stage gene therapy company Genprex Inc. ( GNPX ), a client of NNW devel...
NetworkNewsWire Editorial Coverage : After thirty years of development, gene therapy is seeing a surge of progress and profitability. Gene therapies tackle diseases by altering the genetic makeup of patients’ cells. Recent mergers and research developments make this a promising...
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) announced on February 27 that it has hired Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing. The move to grow the company’s senior te...
Company is Establishing Growth, Solidifying Manufacturing and Supply Chain and Focusing on Strategic Communications in New Year Genprex, Inc. (NASDAQ: GNPX ) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology...
Experienced Biotech Executive Brings More Than 30 Years of Pharmaceutical and Biotechnology Experience to Genprex Genprex, Inc. (NASDAQ: GNPX ) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, ann...
Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney...
Genprex (NASDAQ: GNPX ): Q3 GAAP EPS of -$0.15. More news on: Genprex, Inc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30,...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...